New Study Released Today Showed Patients With Deadly Form of Lung Cancer Lived ...
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that PARAMOUNT, its Phase III study evaluating ALIMTA® (pemetrexed for injection) in the continuation maintenance setting, met its primary endpoint of progression-free survival, or the time a patient is alive without their disease worsening, for patients with a specific type of lung cancer called advanced nonsquamous non-small cell lung cancer (NSCLC)."Continuation maintenance" treatment is when one of the same medicines used in first-line treatment setting is continued as maintenance therapy in an effort to control the cancer.
Results from the study will be presented on Lilly will present overall survival results from PARAMOUNT at a medical meeting in the future.
PARAMOUNT is the second study to evaluate the use of ALIMTA as a maintenance therapy in patients with advanced nonsquamous NSCLC, and the first study to evaluate the use of continuation maintenance with ALIMTA(1) following first-line ALIMTA plus cisplatin therapy.
Results of this multicenter, double-blind trial demonstrated the median progression-free survival measured from randomization (after first-line treatment) was 3.9 months on the ALIMTA arm as compared to 2.6 months on the placebo arm with a hazard ratio of 0.64. Said another way, the study showed that ALIMTA continuation maintenance arm resulted in a 36 percent improvement of survival without disease worsening over the placebo arm. The maintenance disease control rate, or the percentage of patients achieving either a response or stable disease first measured at 6 weeks post-randomization was 71.8 percent (2.8%/69.0%) on the ALIMTA arm and 59.6 percent (0.6%/59.0%) on the placebo arm.
"PARAMOUNT demonstrated that an ALIMTA continuation maintenance regimen—single-agent ALIMTA following ALIMTA plus cisplatin induction therapy—can improve progression-free survival in patients with the most common form of lung cancer," said , M.D., M.B.A., ALIMTA medical product development leader at Lilly Oncology. "This finding continues to validate the use of ALIMTA maintenance treatment for certain patients living with this devastating disease."
A total of 939 patients with advanced nonsquamous NSCLC were enrolled in the study and received ALIMTA (500 mg/m2 on day one of a 21-day cycle) in combination with cisplatin (75 mg/m2) induction therapy. Patients whose disease had not progressed during the ALIMTA+cisplatin induction and had a performance status of 0-1 (n=439) were randomized to receive ALIMTA maintenance (500 mg/m2 on day one of a 21-day cycle) plus best supportive care (n=359) or placebo plus best supportive care (n=180) until disease progression. All patients received vitamin B12, folic acid and dexamethasone.
Injections Sites Nursing - News
Your doctor will give you vitamin B12 injections while you are getting treatment with ALIMTA. You will get your first vitamin B12 injection during the week before your first dose of ALIMTA, and then about every 9 weeks during treatment.
Individuals are suffering from the ravages of long standing injection drug use in towns and cities across Canada. The legal and political battles to keep Insite open leaves other cities and provinces reluctant to open supervised injections sites,
Prohibiting trained non-nursing employees from giving insulin injections "creates a serious obstacle to the ability of California schools to comply with their federal obligations" to educate children with disabilities, the Justice Department argued in
Multiple injection sites were found in the area between Scooler's thigh and groin, one of which was freshly punctured. Traces of blood were found in the toilet and the sink. A used alcohol swab was in the toilet. Scooler, said Damron, had been texting
If the injections successfully take, researchers will use a higher dose in the next phase, hoping to generate sensation and movement. But the process has been slower than anticipated. Only one other patient is taking part in Phase 1.
SmartNurse || Nursing Procedures: LOCATING I.M. INJECTION SITES
Locate the greater trochanter of the femur with the heel of your hand. Then, spread your index and middle fingers from the anterior superior iliac spine to as far along the iliac crest as you can reach. Insert the needle between the two fingers at a 90-degree angle to the muscle. (Remove your fingers before inserting the needle.) Typical injection: 1 to 4 ml (range: 1 to 5 ml). Inject above and outside a line drawn from the posterior superior iliac spine to the greater trochanter of the femur. Or, divide the buttock into quadrants and inject in the upper outer quadrant, about 2″ to 3″ (5 to 7.6 cm) below the iliac crest. Insert the needle at a 90-degree angle. Typical injection: 1 to 4 ml (range: 1 to 5 ml). Use the lateral muscle of the quadriceps group, from a handbreadth below the greater trochanter to a handbreadth above the knee. Insert the needle into the middle third of the muscle parallel to the surface on which the patient is lying. You may have to bunch the muscle before insertion. Typical injection: 1 to 4 ml (range: 1 to 5 ml; 1 to 3 ml for infants).
Injections Sites Nursing - Bookshelf
Textbook of basic nursing
Table 63-2 presents further guidelines for site selection. \J Nursing Alert IM injections must be O given into healthy muscle tissue for proper absorption ...Fundamental Nursing Skills and Concepts
Injection Sites A common site for an intradermal injection is the inner aspect ... Injection Sites The preferred site for giving a subcutaneous injection of ...Lippincott's Nursing Procedures
Select an appropriate injection site. The ventrogluteal site is used ... Remember to rotate injection sites for patients who require repeated injections. ...Clinical Nursing Procedures
Injection site Posterior superior iliac spine Superior gluteal artery Gluteus ... Rotation of injection sites is important for the patient's comfort to ...Foundations of nursing
EVALUATION DOCUMENTATION The client experienced only minimal pain or burning at Medication Administration Record the injection site. ...Day-to-day Guide Directory
Intramuscular Injection: Encyclopedia of Nursing & Allied Health
Intramuscular Injection: Encyclopedia of Nursing & Allied Health ... Intramuscular injections should not be given at a site where there is any indication of pain. Description ...
Z-Track Injection: Encyclopedia of Nursing & Allied Health
Z-Track Injection: Encyclopedia of Nursing & Allied Health ... Rotate the injection sites from one buttock to the other and from site to site. ...
Survey: Nurses Overlook Guidelines for Intramuscular ...
Seven out of 10 hospital nurses who took part in a Canadian study reported using the dorsogluteal buttock site to administer intramuscular injections, ...
Etanercept Injection Site Reaction
: Can you recognize an injection site reaction to etanercept?
Z-track injections
Assess the site immediately after administering the. injection and again 2 to 4 hours ... Select an injection site: the ventrogluteal or deltoid site in adults, the ...